This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Please continue to wear a mask and take all other recommended precautions to guard against COVID-19 infection. The Delta variant is significantly more contagious than previous variants.
CLL Society’s Recommendations for COVID-19 Vaccinated Chronic Lymphocytic Leukemia (CLL) Patients Based on the CDC Updated Considerations for People who are Immunocompromised and on the Underlying Data Dr. Koffman has reviewed the CDC’s guidelines: Interim Public Health Recommendations for Fully Vaccinated People that were updated July 16, 2021, and highlighted key points critical to the wellbeing of our CLL community. Included are the continued warnings that immunocompromised patients should not assume they are protected against COVID-19, close contacts of the immunocompromised should be vaccinated, as well as some nuances concerning how the treatment status of CLL patients might affect response to the COVID-19 vaccine. Read now.
Attend Our Virtual Support Groups!
These self-imposed COVID-19 restrictions are in the best interest of all of us who either have CLL or are caring for or shielding someone who does. You are not alone. Please connect with your local CLL Society CLL-specific Support Group. The emotional rollercoaster you may be experiencing these days is a challenge felt by the more than 2,000 CLL patients and caregivers served by our 39 support groups which meet monthly, nationwide. If you are not familiar with our groups, please enjoy this interviewwith CLL Society’s Director of Support Groups, Terry Evans. Sign-up for the next virtual support group meeting near you. Connect or reconnect now!
LLS COVID-19 Vaccine Response Trial
The results from the LLS COVID-19 vaccine response trial have been eagerly anticipated and they were better than expected with 64% of CLL patients forming antibodies post vaccination.
World CLL Day is Coming!
September 1, 2021, will be the first ever World CLL Day! In partnership with CLL Advocates Network, CLL Society will be celebrating World CLL Day as a time to recognize and raise awareness for all those living with chronic lymphocytic leukemia. We invite you save the date and join us September 1st and join our social media efforts to spread the news.
This year is especially important as we want to use World CLL Day as a time to highlight the vulnerability of the CLL Community during the COVID-19 pandemic. We are taking this first World CLL Day as an opportunity to thank everyone with a healthy immune system for getting the vaccine and helping to protect our community.
In preparation for World CLL Day, CLL Advocates Network is collecting short quotes from CLL patients and caregivers to amplify their experiences through this pandemic. For more detail, and if you would like to share your story, please visit here.
Help Before You Need It!
In case you missed our lead article last week, please know that vaccines and even masks and social distancing, though excellent at slowing the spread of the SARS-CoV-2 virus, will never be 100% protective for everyone, especially the immune-compromised.
The time to prepare for exposure and even infection is now, not post-exposure or when diagnosed with COVID-19. Illness and fear can cloud judgment when one might need to be at their best, thinking clearly and acting quickly.
CLL Society’s simple checklists should be completed, printed out in advance, and stored in an easily accessible location to minimize last-minute scrambles for documents and information. Find appropriate healthcare and access to the best possible treatments, such as monoclonal antibodies that are tailored to the needs of an immunocompromised CLL patient in advance.
Print, complete, and put aside these four potentially life-saving documents:
- Directions for Completing the COVID-19 Planning Checklist
- COVID-19 Planning Checklist: Complete Prior To Exposure
- Household Quarantine Plan
- COVID-19 Action Plan: Do These Things After Testing Positive for COVID-19
Richter’s transformation (a.k.a. Richter’s syndrome) is a rare complication of chronic lymphocytic leukemia (CLL) where the cancer cells transform into a much more aggressive lymphoma. Although Pirtobrutinib (formerly LOXO-305) is probably not a cure for Richter’s transformation, a Phase I/II clinical trial is underway looking at whether it might help stabilize the disease, improve quality of life, and potentially serve as a bridge to other therapies such as CAR-T therapy or stem cell transplant in a subset of patients.
During the virtual European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center. They discussed some promising preliminary results from this clinical trial.
CLL Society Webinar
Join us on August 26th at 10 AM PT, 11 AM MT, 12 PM CT, 1 PM ET for the webinar Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise? Dr. Ian Flinn explains how PI3K inhibitors work, common side effects, and what role they might play in the future for treating CLL.
Join CancerCoach Live and CLL Society this Friday, August 6 at 3 PM ET for a live 1-hour online session, Navigating Treatment with BTK Inhibitors led by Dr. Matthew Davids, Associate Professor of Medicine, Harvard Medical School, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute. It features a patient with BTK Inhibitors perspective on the latest findings on long-term efficacy, side-effect management, and adopting healthy lifestyles to improve outcomes.
Topics to be discussed:
- Challenges managing treatment with BTK inhibitors
- Newly diagnosed and relapsed/refractory settings
- Long-term efficacy of BTK inhibitors
- Adverse-event management
- Healthy lifestyles to improve outcomes
Send your questions to the expert panel.
Continuing medical education activities are required for healthcare providers to maintain their licensing. Rarely do we as patients gain access to their learning materials. CLL Society has partnered with Clinical Care Options to develop an educational activity for healthcare providers who treat patients with CLL. This program features expert insight commentaries, an Interactive Treatment Decision Support Tool, and a series of micro education modules. Not only will this education help improve CLL care for healthcare providers, but it can also help empower and engage patients to become informed participants in shared decision-making. Have a look around in the CLL sections. Explore at your own pace. Learn more about “Optimizing Decision-Making in CLL in an Era of Novel Agents,” and consider sharing this learning opportunity with your healthcare providers. We hope some of this content looks familiar to you!
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.